Humanin

Overview

Humanin is a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene of the mitochondrial genome. It was discovered in 2001 by Nishimoto and colleagues during a functional expression screen for genes that could protect neurons from Alzheimer's disease-related toxicity. This discovery was groundbreaking -- it revealed that mitochondria, long known as cellular powerhouses, also produce bioactive signaling peptides that regulate cell survival.

Humanin belongs to a newly recognized class of molecules called mitochondrial-derived peptides (MDPs), which also includes MOTS-c and SHLPs (Small Humanin-Like Peptides). Together, these MDPs represent a previously unknown layer of retrograde mitochondrial-to-nuclear signaling, with profound implications for aging, neurodegeneration, and metabolic disease.

Key Characteristics

• Origin: Encoded within the mitochondrial 16S rRNA gene (MT-RNR2)
• Classification: Mitochondrial-derived peptide (MDP) / Cytoprotective agent
• Sequence: 24 amino acids (MAPRGFSCLLLLTSEIDLPVKRRA)
• Molecular Weight: 2687.23 g/mol
• Unique Feature: First identified endogenous peptide encoded by mitochondrial DNA with potent anti-apoptotic function

The S14G Analog (HNG)

A critical variant in humanin research is HNG (S14G-Humanin):

• Serine at position 14 replaced with glycine
• Approximately 1,000 times more potent than wild-type humanin
• Greater stability and resistance to degradation
• Most preclinical research uses HNG rather than native humanin
• Considered the primary research tool for humanin studies

Mechanism

Humanin exerts its effects through multiple cellular signaling pathways centered on cytoprotection, metabolic regulation, and anti-inflammatory activity.

Primary Mechanisms

1. Anti-Apoptotic Signaling

Humanin's cornerstone mechanism is the suppression of programmed cell death:

• Binds to and inactivates pro-apoptotic protein Bax, preventing mitochondrial outer membrane permeabilization
• Interacts with IGFBP-3 (Insulin-like Growth Factor Binding Protein 3) to block IGFBP-3-induced apoptosis
• Prevents translocation of Bax from cytosol to mitochondrial membrane
• Blocks cytochrome c release from mitochondria
• Inhibits caspase-3 and caspase-9 activation

2. STAT3 Signaling Pathway

Humanin activates the JAK-STAT3 survival pathway:

• Binds to a trimeric receptor complex (CNTFR/WSX-1/gp130) on the cell surface
• Triggers JAK1/2 kinase activation
• STAT3 phosphorylation and nuclear translocation
• Transcription of survival and anti-inflammatory genes
• This extracellular signaling pathway is independent of mitochondrial localization

3. IGFBP-3 / IGF-1 Modulation

Humanin directly interacts with the insulin/IGF signaling axis:

• Binds IGFBP-3 with high affinity
• Neutralizes IGFBP-3's pro-apoptotic effects
• Modulates IGF-1 bioavailability
• Enhances insulin sensitivity through peripheral and central mechanisms
• Reduces insulin resistance in animal models of metabolic syndrome

4. Mitochondrial Protection

Humanin supports mitochondrial integrity and function:

• Preserves mitochondrial membrane potential under stress
• Reduces mitochondrial reactive oxygen species (ROS) generation
• Enhances mitochondrial biogenesis signaling
• Supports electron transport chain complex function
• Prevents stress-induced mitochondrial fragmentation

Cellular Effects

At the cellular level, humanin:

• Protects neurons against amyloid-beta toxicity (Alzheimer's model)
• Prevents serum-starvation-induced cell death
• Reduces endoplasmic reticulum (ER) stress
• Enhances autophagy (cellular cleanup)
• Modulates calcium homeostasis

Research

Neurodegeneration and Alzheimer's Disease

Amyloid-Beta Protection

The initial discovery of humanin was in the context of Alzheimer's disease:

• Humanin directly blocks amyloid-beta (Abeta) peptide-induced neuronal death
• HNG (S14G-Humanin) prevents Abeta1-42 toxicity at nanomolar concentrations
• Reduces Abeta plaque formation in transgenic Alzheimer's mouse models
• Improves spatial learning and memory in APP/PS1 mice
• Prevents tau hyperphosphorylation through GSK-3beta modulation

Other Neurodegenerative Conditions

• Protects against prion protein-induced neuronal death
• Reduces damage in cerebral ischemia/stroke models
• Attenuates oxidative stress-induced neuronal loss
• Potential applications in Parkinson's disease (dopaminergic neuron protection)

Metabolic Disease

Insulin Sensitivity and Diabetes

Humanin shows significant metabolic effects:

• Improves insulin sensitivity in diet-induced obesity models
• Reduces hepatic glucose output
• Enhances peripheral glucose uptake
• Circulating humanin levels inversely correlate with insulin resistance in humans
• Centrally administered humanin improves whole-body glucose homeostasis via hypothalamic signaling

Cardiovascular Protection

• Reduces atherosclerotic plaque formation in ApoE-knockout mice
• Protects cardiomyocytes against ischemia-reperfusion injury
• Reduces oxidative stress in endothelial cells
• Attenuates vascular inflammation

Aging and Longevity

Biomarker of Aging

Human observational studies reveal important patterns:

• Circulating humanin levels decline progressively with age
• Lower humanin levels correlate with age-related diseases
• Children of centenarians have higher circulating humanin than age-matched controls
• Humanin levels predict mitochondrial function in elderly populations
• GH/IGF-1 axis negatively regulates humanin production

Lifespan Effects

• Long-lived animal models (naked mole rats, growth hormone receptor knockout mice) have elevated humanin levels
• Caloric restriction, which extends lifespan, increases humanin expression
• Supplementation with HNG extends healthspan markers in animal models

Ophthalmic Protection

Humanin demonstrates retinal protective effects:

• Prevents oxidative stress-induced retinal pigment epithelium (RPE) cell death
• Potential therapeutic relevance for age-related macular degeneration (AMD)
• Protects against light-induced retinal damage in animal models

Dosing

Research Protocols

Administration Notes

Subcutaneous Injection

• Most practical route for research use
• Inject into abdominal subcutaneous tissue
• Rotate injection sites
• Morning administration preferred

Intravenous Administration

• Used in some animal research protocols
• Provides most reliable pharmacokinetics
• Requires clinical supervision

Important Considerations

• HNG (S14G analog) is approximately 1,000x more potent than native humanin
• Dosing of HNG is substantially lower than wild-type humanin
• No established dose-response relationship in humans
• Short half-life may necessitate multiple daily administrations or sustained-release formulations

Reconstitution

When using lyophilized humanin:

• Reconstitute with bacteriostatic water or sterile saline
• Gently swirl; do not vortex (may denature peptide)
• Store reconstituted solution refrigerated (2-8C)
• Use within 7 days of reconstitution

Pharmacokinetics

Absorption

• Subcutaneous: Rapid absorption, peak levels within 10-15 minutes
• Intravenous: Immediate systemic distribution, 100% bioavailability
• Subcutaneous bioavailability estimated at ~70%

Distribution

• Circulates in plasma bound to IGFBP-3 and albumin
• Crosses the blood-brain barrier (CNS effects demonstrated)
• Distributes to metabolically active tissues (brain, heart, liver, muscle)
• Concentrates at sites of cellular stress

Metabolism

• Rapidly degraded by circulating and tissue peptidases
• Protein binding (IGFBP-3) partially protects from degradation
• No known CYP450 interactions
• Metabolized to constituent amino acids

Elimination

• Half-life: Approximately 30 minutes (native humanin)
• HNG analog may have modestly extended half-life
• Despite short half-life, downstream signaling effects persist
• Gene expression changes and survival pathway activation outlast circulating peptide

Synergy & Stacking

Humanin may be combined with other cytoprotective and anti-aging peptides for comprehensive cellular protection.

Common Combinations

Humanin + Epitalon

Dual anti-aging strategy:

• Humanin protects mitochondrial function and prevents apoptosis
• Epitalon activates telomerase for genomic maintenance
• Addresses two fundamental aging mechanisms simultaneously
• Complementary cellular protection

Humanin + Semax

Neuroprotective stack:

• Humanin prevents neuronal apoptosis (especially Abeta-mediated)
• Semax enhances BDNF and neuroplasticity
• Different mechanisms of neuroprotection provide broader coverage
• Humanin SubQ + Semax intranasal for optimal delivery

Humanin + MOTS-c

Mitochondrial peptide combination:

• Both are mitochondrial-derived peptides (MDPs)
• Humanin focuses on cell survival/anti-apoptosis
• MOTS-c focuses on metabolic regulation and exercise mimicry
• Together they represent comprehensive mitochondrial signaling support

Timing Considerations

• Morning administration preferred to align with metabolic rhythms
• Short half-life may benefit from split dosing (morning and afternoon)
• No known food interactions, but administer away from meals for consistency
• Allow 30 minutes between different peptide injections

Safety

Known Side Effects

Safety data for humanin is limited to preclinical observations and early human biomarker studies:

Observed in Animal Studies

• Generally well-tolerated at research doses
• No significant organ toxicity at standard experimental doses
• Mild injection site reactions (swelling, redness)
• Transient hypoglycemia at high doses (via insulin sensitization)

Theoretical Concerns

• Anti-apoptotic mechanism could theoretically promote cancer cell survival
• Interaction with IGF-1 signaling may have complex metabolic effects
• Long-term effects unknown

Contraindications

Avoid use if:

• Active cancer or history of malignancy (anti-apoptotic effects could promote tumor survival)
• Pregnant or breastfeeding
• Under 18 years of age
• Undergoing chemotherapy or radiation therapy

Drug Interactions

• Potential synergy/interference with insulin and glucose-lowering medications
• Contraindicated during active chemotherapy (anti-apoptotic opposition)
• No significant CYP450 interactions expected
• Monitor blood glucose when combining with metabolic medications

Monitoring

Baseline Assessments

Before considering humanin use:

• Comprehensive metabolic panel (fasting glucose, insulin, HbA1c)
• Cancer screening appropriate for age and risk factors
• Mitochondrial function markers if available (lactate, CoQ10 levels)
• Cognitive assessment if using for neuroprotective purposes
• Complete blood count

During Use

• Monitor fasting glucose and insulin sensitivity
• Track any signs of hypoglycemia
• Observe injection site reactions
• Document cognitive or functional changes
• Monitor for any unusual growth or masses

Post-Protocol

• Repeat metabolic panel
• Reassess cognitive function
• Compare to baseline measures
• Evaluate need for continued use

Regulatory

Current Status

Research Landscape

• Discovered in 2001 at Keio University School of Medicine, Japan
• Active research programs at USC (Pinchas Cohen laboratory), Keio University, and others
• Over 500 peer-reviewed publications on humanin and related MDPs
• Several patents filed for humanin analogs and formulations
• Growing interest in humanin as an aging biomarker
• No completed Phase I clinical trials as of current literature

References